Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AIDS/HIV Vaccine
DNA prime-MVA boost HIV vaccine tailored for eastern and central Africa
September 5th, 2004
Researchers have developed a DNA prime-MVA boost HIV vaccine tailored for eastern and central Africa. According to a study from England, "For the development of human immunodeficiency virus type 1 (HIV-1) vaccines, traditional approaches inducing virus-neutralizing antibodies have so far failed. Thus the effort is now focused on elicitation of cellular immunity. We are currently testing in clinical trials in the United Kingdom and East Africa a T-cell vaccine consisting of HIV-1 clade A Gag-derived immunogen HIVA delivered in a prime-boost regimen by a DNA plasmid and modified vaccinia virus Ankara (MVA)." "Here, we describe engineering and...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
